NCT00885157已完成2 期
Immunogenicity and Safety of Fractional Booster Dose of Sanofi Pasteur's Inactivated Poliomyelitis Vaccine (IMOVAX Polio) Administered Intradermally Versus Full Booster Dose of Inactivated Poliomyelitis Vaccine (IMOVAX Polio) Administered Intramuscularly at 15 to 18 Months of Age in Healthy Toddlers in The Philippines
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 225
- 试验地点
- 1
- 主要终点
- Safety: To provide information concerning the safety after booster intradermal administration of IPV vaccine
研究概览
简要总结
The purpose of this study is to investigate the use of a fourth fractional booster dose of sanofi pasteur's IMOVAX Polio injected intradermally (using the Mantoux technique) as booster dose between 15 to 18 months of age, in terms of immunogenicity and safety.
Objectives:
- To describe in each group the immunogenicity of IMOVAX Polio administered intradermally or intramuscularly, one month after the booster dose given at 15-18 months of age in toddlers previously primed with three doses of IMOVAX Polio vaccine during the IPV25 study.
- To describe in each group the safety of the booster dose of IMOVAX Polio vaccine administered intradermally or intramuscularly.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 15 Months 至 18 Months（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Aged 15 to 18 months on the day of inclusion
- •Informed consent form signed by the parent(s) or other legally acceptable representative
- •Subjects and parent/guardian able to attend all scheduled visits and comply with all trial procedures
- •Child having completed all visits of the IPV25 study (NCT00604058), including the three-dose primary vaccination series with the study vaccine (IMOVAX Polio), using the route of administration as designated by randomization.
排除标准
- •Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the trial vaccination
- •Planned participation in another clinical trial during the present trial period
- •Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy
- •Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances
- •Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the investigator
- •Receipt of blood or blood-derived products since birth that might interfere with the assessment of immune response
- •Receipt of any vaccine in the 4 weeks preceding the trial vaccination
- •Planned receipt of any vaccine during the present trial period
- •Known personal or maternal Human Immunodeficiency Virus (HIV), Hepatitis B antigen or Hepatitis C seropositivity
- •History of seizures
- •History of poliomyelitis infection (confirmed either clinically, serologically or microbiologically)
- •Previous fourth dose vaccination against the poliomyelitis disease with either the trial vaccine or another vaccine
- •Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion contraindicating IM injection
- •Febrile illness (temperature ≥38.0 °C) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment.
结局指标
主要结局
Safety: To provide information concerning the safety after booster intradermal administration of IPV vaccine
时间窗: 30 days post-vaccination and entire study duration
Immunogenicity: To provide information concerning the immunogenicity of IPV vaccine administrated intradermally as a booster vaccination.
时间窗: 30 days post-vaccination
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses IntramuscularlyPoliomyelitisNCT00604058Sanofi Pasteur, a Sanofi Company236
进行中（未招募）
不适用
Immunogenicity and Safety of a Fractional Booster Dose of IPV Intradermally Versus Full Dose IntramuscularlyPoliomyelitisEUCTR2015-005184-16-Outside-EU/EEASanofi Pasteur SA225
已完成
3 期
Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate VaccineMeningococcal InfectionsMeningococcal MeningitisMeningitisNCT02752906Sanofi Pasteur, a Sanofi Company810
已完成
2 期
Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)Acellular PertussisHaemophilus Influenzae Type bPoliomyelitisHepatitis BTetanusDiphtheriaNCT01453998GlaxoSmithKline657
已完成
3 期
Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With PrevnarStreptococcus PneumoniaeNCT00594347Sanofi Pasteur, a Sanofi Company339